drugset
drugset / Trial / NCT00474552

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315

NCT00474552 ↗

Phase 1 Terminated 56 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

Primary: To assess the safety and tolerability of ascending multiple oral doses of SAM-315, an investigational drug, in healthy young adult and elderly subjects. Secondary: To assess the Pharmacokinetic and Pharmacodynamic profiles of multiple oral doses of SAM-315 in healthy young adult and elderly subjects.

Timeline

Start
2007-06
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject SAM-315 Unknown 0.2 mg Oral
Subject SAM-315 Unknown 0.5 mg Oral
Subject SAM-315 Unknown 1 mg Oral
Subject SAM-315 Unknown 2 mg Oral

Indications

Alzheimer disease